Crispr Therapeutics Ag (CRSP) — 10-Q Filings

All 10-Q filings from Crispr Therapeutics Ag. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

CRISPR Therapeutics' Net Loss Widens to $451M Amid R&D Shifts — Nov 10, 2025 Risk: high
CRISPR Therapeutics AG reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $450.986 million, up from $328.941 mil
CRISPR Revenue Plunges 90% Amid Vertex Collaboration Shift — Aug 4, 2025 Risk: high
CRISPR Therapeutics AG reported collaboration revenue of $1.0 million for the three months ended June 30, 2025, a significant decrease from $10.0 million in the
CRISPR Therapeutics AG Files Q1 2025 10-Q — May 6, 2025 Risk: medium
CRISPR Therapeutics AG filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31st. Key financial data and business act
CRISPR Therapeutics Q3 2024 Update — Nov 5, 2024 Risk: medium
CRISPR Therapeutics AG filed its Q3 10-Q report for the period ending September 30, 2024. The company reported collaboration revenue for the nine months ended S
CRISPR Therapeutics AG Files Q2 2024 10-Q — Aug 5, 2024 Risk: medium
CRISPR Therapeutics AG filed a 10-Q for the period ending June 30, 2024. The company reported on its financial position and business activities, including detai
CRISPR Therapeutics AG Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk: medium
CRISPR Therapeutics AG (CRSP) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. CRISPR Therapeutics AG filed a 10-Q report for the period ending Marc

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX